International Headlines and Stories

A small defect of throttle and it's a catastrophe for PSA. The group just defeated the recall of nearly 100,000 cars. "PSA will preventively a recall on these vehicles, the versions that could have the same defect pedal," said a spokesman for the firm. This concern of Peugeot 107 and Citroen C1 produced between February 2005 and August 2009 in the Kolin plant in the Czech Republic, that is to say "10% of the park from C1 and 107 stock, less than 100,000 cars" in Europe, added the spokesman.

Around 220,000 Peugeot and Citroën released each year of the plant, operational since February 2005 but "only a portion of production is concerned because according to the versions, gasoline or diesel, this is not the same type of elements" that is used, he said.Both urban French car manufacturer are assembled on the assembly lines of Toyota, which produces Kolin his little Aygo. This model is one of eight that the Japanese manufacturer decided to recall in Europe for a lack of accelerator pedal.

But virtually all components of the three models are the same, which explains why PSA is also forced to recall cars. In this context, the French manufacturer will "study in the coming days and weeks with the procedures for Toyota this season" reminder, "added the spokesman.

"The limits of the Toyota"

On paper, PSA and Toyota are equal partners in their joint venture TPCA (Toyota Peugeot Citroën Automobile) which manages the site of Kolin.But in reality, it is indeed a Toyota, the Japanese are in charge of designing and manufacturing vehicles free business cards .

For CGT Peugeot Sochaux (Doubs), the recall of vehicles demonstrates "the limits of the Toyota, denouncing a kind of production with" the minimum time to study and design of facilities, personnel and wages " and "no talk of outsourcing to the death."

The crisis facing Toyota is the task of oil and other manufacturers. Before PSA, the U.S. Ford has suspended production as a precaution for some commercial vehicles in China using the same faulty accelerator pedal as Toyota. This measure concerns, however, less than 2,000 vehicles. Besides the joint venture with PSA, Toyota owns with another Japanese, Subaru.Their factory is located in Indiana, the United States.

Toyota is forced to recall millions of cars around the world for lack of accelerator pedal detected in the United States, Canada, China and Europe. Nothing the United States, 2.3 million vehicles have been recalled over 270,000 points of Canada and 75,000 in China.

In Europe, the number of affected vehicles could reach 1.8 million. Eight models are concerned: AYGO, iQ, Yaris, Auris, Corolla Verso, Avensis and RAV4. The number of cars each country concerned should be seen "running next week," said the spokesman for Toyota.

The Japanese giant's chairman, Akio Toyoda, apologized Saturday for this one problem.World leading manufacturer since 2008, Toyota had already experienced a technical problem that forced him to recall cars in the United States due to a defect in the carpet can also block the accelerator

lefigaro.fr: Pay rates are eroding each year. Life insurance will she lose her place of savings product preferred French?

François Longin: This term is preferred savings often used but it is not really the case for at least two reasons. The first is financial. The product units accounts sitting on the CAC 40 have suffered from the crisis. As for funds in euro, eroding their earnings. 5%, it rose to 4.5% or 3.8% for some. But with returns that remain between 3% to 4%, life insurance remains more attractive than money market products whose performance flirts with 1%.The second reason is related to the reform of inheritance tax since 2007 has lost a little interest in life insurance.

Life insurance is it still a good product transmission?

The tax rules for the transmission of money invested in life insurance have not changed, but the reform of inheritance taken by the Government to facilitate such donations, has lost its interest in life insurance. Particularly as regards the succession between spouses. However, holders of life insurance can now pay up to 150,000 euros to each of their children, not inheritance. This allows for example a couple with two children to give each of them 300,000 euros for free.Beyond 150,000 euros, the transmission is taxed at 20%.

What issues should I consider before choosing a contract of life insurance?

Before choosing an insurance-life, we must address three key points. The profitability, risk and liquidity funds. Profitability, in other words, the compensation offered by the contract is important. It will depend on the type of support. Either you invest in a fund in euros, based on government bonds and the yield will be between 3.5% and 4.80%. Whether you choose the fund units of account, also called multichannel, whose performance is more important because you take more risks by investing in shares or funds to emerging markets. It's more risky, but the year after, people who have invested in French shares have gained 20%.

It must then linger on the liquidity of funds.The money is not actually blocked, but it is more or less detrimental to withdraw money before age 8.

Finally, we must be vigilant about fees: entry fees, which disappear on the Internet, and management fees that range between 0.6% and 1% under the contracts.

At what age is it interesting to take out life insurance?

The tax treatment of life changes during the life of the insured. Over the insured later withdrew the money invested is more interesting. Insurers therefore recommend to take a contract as soon as practicable, to date, and this even if the person is simply placing a small capital without making further payments in the first place.When young, you can also take more risk and choose unit-linked contracts account for more attractive returns.

Can we rely on contracts offered on internet?

They are good products in the sense that it has internet access to the same fund as the insurance contracts traded in the "real world", with more direct access to place orders. Other service not found with traditional life assurance: all orders have a written record, the process is to me more reliably than through an intermediary. The sites of online brokerage also offers advice and simulations. Opting for a contract on the internet, however, implies that one has some experience of financial investments.

Fight against the invasion of generics has become the creed of Sanofi-Aventis. The pharmaceutical group multiplies acquisitions for several months to cope with the loss of patents on some of its drugs by 2014. Latest news dated from Voices? A stake of 19.9% in the Danish biotech company Zealand Pharma for 100 million euros. The interest of the maneuver is to get his hands on the ZP10, a treatment against diabetes and obesity currently in phase three clinical trials, the last before the placing on the market. It also aims to strengthen an existing partnership with the company valued at between 400 and 500 million euros. In exchange, the news caused investors to react moderately. The title takes Sanofi 1.68% to 56.33 euros.

The ZP10, is baptized by AVE0010 Sanofi, should be launched on the market in 2012.Sanofi wants to be the successor of Lantus insulin his star, who in 2008 has already generated 2.4 billion euros in sales and has raised a number of sales of laboratory medicine in the first nine months of 2009. The pharmaceutical group is already preparing the loss of patent for this drug in Europe and the United States in 2014. So in addition to the ZP10, Sanofi is testing a new version of Lantus. If it successfully passes the test, he could receive a patent until 2025.

Being on all fronts

Since the beginning of the year, Sanofi is trying every means to expand its portfolio. In addition to equity from Zealand Pharma, the group also focuses its activity in atrial fibrillation, a heart disorder.

On Monday, Sanofi announced the acquisition of Chattem, a leading drug sold without prescription in the United States, for 1.9 billion dollars.An operation that should allow him to become the No. 5 global counter medications. A segment very promising since it generated 86.6 billion dollars worldwide in 2008 with 20 billion in the United States. On this market alone, it was the fifth acquisition made by Sanofi-Aventis between 2008 and 2009, after the Australian Symbion, the Argentine Gramon, the French specialist food supplements and beauty products Kernpharm the Netherlands last month.

Other operations were performed in the generic (Medley, Kendrick, Zentiva), ophthalmology (Fovea), vaccine (Shantha) or in animal health with the purchase for 2.8 billion euros of the 50 % of its U.S. partner in the Merck Merial Veterinary Laboratory. Recently, market rumors evoked recovery of German Ratiopharm fourth generic manufacturer in the world, boosted as the stock market.

In total, Chris Viehbacher, head of Sanofi-Aventis since December 2008, launched 31 acquisitions and partnerships in 2009. And the movement should continue in 2010.

ALSO READ:

"There is a gap between image and reality of our group"

Beijing celebrates this anniversary fanfare since late November. An exhibition devoted to the achievements of Macao since the handover was opened December 11 in Beijing by Chinese President Hu Jintao. "Macau has grown tremendously during the last decade," he told the Chinese press. Development supported by the central government of China, he said.

Macau and China signed in 2003 a trade agreement (the CSIO), strengthened several times since. This agreement facilitates the access of goods and services macanas to mainland China. The trade has more than tripled between 1999 and 2008, reaching $ 2.91 billion last year.According to a report released December 16 by the Ministry of Commerce of China, mainland China was the third largest investor in Macao in late September, after the United States and the European Union, a non-financial direct investment of 623 million dollars.

Jubilation in the city of Macau, just after the handover ceremony. Photo credits: AFP